Abstract library

9 results for "Eriksson".
#112 Chromogranin A is a sensitive marker for detection of recurrence in neuroendocrine tumors
Introduction: The chromogranin family is a family of large acidic proteins which are expressed in neuroendocrine cells. There are several members in this family (Chromogranin A, B (CgA and CgB) and the secretogranins). Here, we show that CgA is an excellent marker to detect recurrence in neuroendocrine tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eva Tiensuu Janson
#173 Temozolomide in Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment thus far have been disappointing. Temozolomide has, however, shown some activity in a small prior study.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel P Lindholm
#178 Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ass Prof Dan Granberg
#196 Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study
Introduction: The combination of Streptozotocin with 5-FU has been used during the past decades in our institution as the first-line treatment in pancreatic NETs with low to moderate proliferation.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Pantelis Antonodimitrakis
#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP
Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Gordana Kozlovacki
#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby
#906 Secondary Hormonal Syndromes in Patients with Sporadic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) are characterized by secretion of peptide hormones that may cause distinct syndromes. Although most patients with hormonal secretion are diagnosed upon primary diagnosis, a significant proportion of pancreatic NET patients develop secondary hormonal production later on in the disease.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Joakim Crona
Authors: Crona J, Eriksson B, Welin S, ...
#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease
Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: PhD Valeria Giandomenico
#1587 LRIG1 Was Down-Regulated in Medullary Thyroid Cancer but No Significant Effect of LRIG1 Was Found in RET2B Transgenic Mice and Human Differentiated Thyroid Cancer
Introduction: There are four main types of thyroid cancer, papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic. In both PTC and MTC, genomic rearrangements and point mutations in the proto-oncogene RET are common. RET encodes a receptor tyrosine kinase that is negatively regulated by leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1). LRIG1 gene status and mRNA and protein expression correlate with patient survival in different types of cancer.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Associate profes David Lindquist
Keywords: LRIG1, RET, MTC